NASDAQ · CMND
Healthcare · Biotechnology
$6.00
Down-$0.16 (-2.67%)
Updated Oct 6, 2026, 11:13 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CMND
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CMND closed at $6.00 after 20 trading sessions, up 482.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $5.93 | $6.54 | $5.25 | $6.00 | 92.04K |
| Oct 2, 2026 | $5.92 | $5.92 | $5.644 | $5.72 | 12.61K |
| Oct 1, 2026 | $5.9984 | $6.0944 | $5.6744 | $5.7264 | 27.67K |
| Sep 30, 2026 | $6.516 | $6.7192 | $6.4008 | $6.4409 | 12.47K |
| Sep 29, 2026 | $6.2584 | $6.5746 | $6.2584 | $6.4912 | 5.19K |
| Sep 28, 2026 | $0.8001 | $0.818 | $0.7826 | $0.7877 | 91.66K |
| Sep 25, 2026 | $0.84 | $0.84 | $0.8021 | $0.803 | 58.11K |
| Sep 24, 2026 | $0.8508 | $0.8508 | $0.80 | $0.8103 | 65.53K |
| Sep 23, 2026 | $0.804 | $0.85 | $0.78 | $0.85 | 373.67K |
| Sep 22, 2026 | $0.78 | $0.79 | $0.7723 | $0.7812 | 76.26K |
| Sep 21, 2026 | $0.79 | $0.7999 | $0.7751 | $0.7906 | 122.88K |
| Sep 18, 2026 | $0.85 | $0.8584 | $0.77 | $0.7994 | 194.7K |
| Sep 17, 2026 | $0.8244 | $1.06 | $0.8129 | $0.858 | 1.6M |
| Sep 16, 2026 | $0.841 | $0.8469 | $0.79 | $0.8059 | 154.04K |
| Sep 15, 2026 | $0.918 | $0.9329 | $0.8333 | $0.8643 | 168.73K |
| Sep 14, 2026 | $0.94 | $0.9698 | $0.9173 | $0.944 | 168.85K |
| Sep 11, 2026 | $0.9998 | $1.06 | $0.95 | $0.9667 | 288.31K |
| Sep 10, 2026 | $1.00 | $1.045 | $0.9803 | $0.9816 | 102.84K |
| Sep 9, 2026 | $1.07 | $1.11 | $1.00 | $1.06 | 336.83K |
| Sep 8, 2026 | $1.15 | $1.15 | $0.9199 | $1.03 | 3.12M |
The latest Smart Investors Daily articles mentioning CMND.
Company
Market Activity
Research & News
CMND research
Company profile and research snapshot.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 30, 2026
learmind Medicine Inc. (the "Company") is announcing that it will effect a reverse share split of the Company’s common shares at the ratio of 1-for-8, such that each eight (8) common shares, no par value, shall
Yahoo · Sep 23, 2026
The U.S. Patent Applications Cover Proprietary Combinations of NeuroThera's PEA Technology With LSD, Ketamine and Ibogaine for Potential Therapeutic Applications, Including Mental Health Disorders, Such as Depression and PTSD as Well as Substance Use...
Yahoo · Sep 23, 2026
The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developi
Yahoo · Sep 23, 2026
The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disorders Vancouver, Canada, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcoh
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CMND.
No results
No recent SID articles mention CMND.
